Relative to glucagon administration and relative to the dispenser report under the controlled drug prescription health and safety program.
Impact
The adjustments made by SB289 could have implications on how health care providers administer glucagon. By formalizing the terminology related to glucagon and expanding the meanings associated with its administration, the bill could facilitate better understanding and adherence to glucagon use in emergency and other medical situations. Furthermore, it may streamline the processes surrounding patient management and prescription reporting for controlled substances.
Summary
Senate Bill 289 is focused on the administration of glucagon and introduces changes to the reporting requirements under the controlled drug prescription health and safety program. Specifically, the bill revises statutory language by replacing references to ' glucagon injections' with 'glucagon administration', suggesting a broadened scope for the application of glucagon beyond just injections. This amendment aims to clarify and modernize the understanding and management of glucagon use in medical practices.
Contention
While the bill appears straightforward, discussions surrounding its implementation may reveal varying perspectives on health and safety regulations. Some stakeholders may contend that clearer definitions and precise regulations will lead to improved patient care, while others might raise concerns over how such regulations could affect medical practice operations or lead to overregulation.
Notable_points
The bill also introduces a requirement for additional details in the dispenser report, specifying the format of prescriptions—whether they are electronic, faxed, written, or oral. This change aims to enhance record-keeping and tracking of drug prescriptions within the controlled health and safety framework.
Relative to membership, jurisdiction, and reports of the health care workplace safety commission and relative to health care facility reporting requirements under the workplace violence prevention program.
Relates to the dispensing of glucagon; authorizes a pharmacist to dispense any Food and Drug Administration approved glucagon medication to an insulin using person regardless if the person currently has or previously has had a prescription for glucagon.